Antiplatelet Therapy to Prevent Stroke in African Americans

Completed

Phase 4 Results

Results

Ticlopidine had less than 1% efficacy when compared to aspirin and had no statistically significant difference in preventing recurrent stroke, myocardial infarction, or vascular death.